Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
R&D
Biotech
JPM: Novo CSO craves 'different flavors' of pipeline innovation
Novo is seeking to strengthen its obesity offerings while pursuing other indications that intersect with metabolism.
Darren Incorvaia
Jan 13, 2026 7:45am
Pharma's 'urgent need for reinvention': PwC's call to action
Jan 8, 2026 6:00am
After $4.8B Amicus buy, BioMarin drops genetic disease asset
Dec 22, 2025 11:12am
FDA's 1-trial approval plan would boost R&D spend: Jefferies
Dec 5, 2025 11:00am
Valneva closes site to consolidate R&D footprint, lays off 30
Nov 26, 2025 12:57pm
Value of AI biotechs nearly double that of peers: PitchBook
Nov 26, 2025 10:34am